Esthesioneuroblastoma Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
Conditions: Somatostatin Receptor Positive CNS Tumors; Meningioma; Esthesioneuroblastoma; Hemangioblastoma; Medulloblastoma; Paraganglioma; Pituitary Adenoma Intervention: Diagnostic Test: Ga68-DOTATATE-PET/MRI Sponsor: Weill Medical College of Cornell University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 9, 2019 Category: Research Source Type: clinical trials

68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
Conditions: CNS Tumors; Meningioma; Esthesioneuroblastoma; Hemangioblastoma; Medulloblastoma; Paraganglioma; Pituitary Adenoma Intervention: Diagnostic Test: Ga68-DOTATATE-PET/MRI Sponsors: Weill Medical College of Cornell University; Novartis Pharmaceuticals Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 9, 2019 Category: Research Source Type: clinical trials

68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
Conditions: CNS Tumors; Meningioma; Esthesioneuroblastoma; Hemangioblastoma; Medulloblastoma; Paraganglioma; Pituitary Adenoma Intervention: Diagnostic Test: Ga68-DOTATATE-PET/MRI Sponsor: Weill Medical College of Cornell University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 9, 2019 Category: Research Source Type: clinical trials

Esthesioneuroblastoma: Outcomes After Treatment
Condition: Esthesioneuroblastoma, OlfactoryIntervention: Sponsor: Ricardo L. Carrau, MDRecruiting - verified October 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2015 Category: Research Source Type: clinical trials